Browsing by Author Schwabe, C

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 1 to 11 of 11
TitleAuthor(s)Issue DateViews
 
A phase 1 study to evaluate safety and tolerability of escalating single doses of the hepatitis B virus RNA interference drug ARC-521 in a healthy volunteer population
Proceeding/Conference:Journal of Hepatology
Gane, ESchwabe, CGiven, BSchluep, THamilton, JLai, CLLocarnini, SLau, JFerrari, CGish, R
2017
64
 
Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection
Journal:Gastroenterology
Yuen, MFGane, EJKim, DJWeilert, FChan, HLYLalezari, JHwang, SGNguyen, TFlores, OHartman, GLiaw, SLenz, OKakuda, TNTalloen, WSchwabe, CKlumpp, KBrown, N
2019
28
 
Dose response with the RNA interference (RNAi) therapy JNJ-3989 combined with nucleos(t)ide analogue (NA) treatment in expanded cohorts of patients (pts) with chronic hepatitis B (CHB)
Proceeding/Conference:Hepatology
Gane, EJLocarnini, SLim, THStrasser, SISievert, WCheng, WThompson, AGiven, BDSchluep, THamilton, JBiermer, MKalmeijer, RBeumont-Mauviel, MLenz, OCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGYuen, RMF
2019
10
 
First results with RNA interference (RNAi) in chronic hepatitis b (CHB) using ARO-HBV
Proceeding/Conference:Hepatology
Gane, EJLocarnini, SLim, THStrasser, SSievert, WCheng, WThompson, AGiven, BSchluep, THamilton, JLi, ZCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGYuen, RMF
2018
56
 
Interim safety, tolerability pharmacokinetics, and antiviral activity of ABI-H0731, a novel core protein allosteric modulator, in healthy volunteers and non-cirrhotic viremic subjects with chronic hepatitis B
Proceeding/Conference:Journal of Hepatology
Yuen, RMFAgarwal, KGane, ESchwabe, CCheng, WSievert, WKim, DJAhn, SHLim, YSVisvanathan, KRuby, ELiaw, SColonno, RLopatin, U
2018
101
 
Resistance monitoring data from treatment-naïve chronic HBV infected patients treated for 28 days with a new class a core protein allosteric modulator RO7049389 monotherapy
Proceeding/Conference:Journal of Hepatology
Zhou, XKazma, RMeinel, DZhou, YYuen, RMFGane, ESchwabe, CTanwandee, TCao, LZhou, JBo, Q
2020
12
 
RO7049389, a core protein allosteric modulator, demonstrates robust anti-HBVactivity in chronic hepatitis B patients and is safe and well tolerated
Proceeding/Conference:Journal of Hepatology
Gane, ELiu, AYuen, RMFSchwabe, CBo, QDas, SGoa, LZhou, XWang, YCoakley, EJin, Y
2018
62
 
RO7049389, a core protein allosteric modulator, is safe and well tolerated in healthy volunteers and demonstrates potent anti-HBV activity in a phase 1 trial
Proceeding/Conference:Journal of Viral Hepatitis
Gane, ELiu, AYuen, RMFSchwabe, CBo, QDas, SBGoa, LZhou, XWang, YCoakley, EJin, Y
2018
85
 
Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial
Journal:The Lancet Gastroenterology & Hepatology
Yuen, MFAgarwal, KGane, EJSchwabe, CAhn, SHKim, DJLim, YSCheng, WSievert, WVisvanathan, KRuby, ELiaw, SYan, RHuang, QColonno, RLopatin, U
2020
22
 
Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg < 100 IU/ml threshold
Proceeding/Conference:Journal of Hepatology
Yuen, RMFLocarnini, SLim, THStrasser, SSievert, WCheng, WThompson, AGiven, BSchluep, THamilton, JCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGGane, E
2019
48
 
Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen suppression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment
Proceeding/Conference:Journal of Hepatology
Gane, ELocarnini, SLim, THStrasser, SSievert, WCheng, WThompson, AGiven, BSchluep, THamilton, JBiermer, MKalmeijer, RBeumont-Mauviel, MLenz, OCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGYuen, RMF
2020
36
Showing results 1 to 11 of 11